Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sildenafil citrate, quantity: 140.4 mg (equivalent: sildenafil, qty 100 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; copovidone; croscarmellose sodium; saccharin sodium; indigo carmine aluminium lake; calcium hydrogen phosphate; magnesium stearate - noumed sildenafil is indicated for the treatment of erectile dysfunction in adult males. noumed sildenafil is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - sildenafil citrate, quantity: 70.2 mg (equivalent: sildenafil, qty 50 mg) - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; croscarmellose sodium; microcrystalline cellulose; calcium hydrogen phosphate; magnesium stearate; copovidone; saccharin sodium - noumed sildenafil is indicated for the treatment of erectile dysfunction in adult males. noumed sildenafil is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - raloxifene hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - raloxifene hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; polysorbate 80; povidone; microcrystalline cellulose; magnesium stearate; glycine; titanium dioxide; hypromellose; carnauba wax; macrogol 400 - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; citric acid monohydrate; macrogol 400; polysorbate 80; titanium dioxide; hypromellose; microcrystalline cellulose; crospovidone - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: polysorbate 80; magnesium stearate; hypromellose; crospovidone; citric acid monohydrate; microcrystalline cellulose; titanium dioxide; macrogol 400; povidone - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; macrogol 400; microcrystalline cellulose; magnesium stearate; titanium dioxide; povidone; citric acid monohydrate; polysorbate 80 - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 400; povidone; microcrystalline cellulose; crospovidone; citric acid monohydrate; polysorbate 80; titanium dioxide; magnesium stearate - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 28.1 mg (equivalent: sildenafil, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; croscarmellose sodium; calcium hydrogen phosphate; titanium dioxide; lactose monohydrate; triacetin - used to treat patients with pulmonary arterial hypertension classified as who functional classes ii and iii, to improve exercise capacity. efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. the efficacy of sildenafil citrate 20 mg has not been evaluated in patients currently on bosentan therapy.